AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02898571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparitor
Study NCT02898571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Active treatment
Study NCT02898571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: epicatechin
Description: Active treatment
Study NCT01266720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1, VEGFR2
Description: One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
Study NCT01266720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
Study NCT00729222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: rolofylline placebo IV infusion over 4 hours.
Study NCT00729222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV infusion over 4 hours.
Study NCT04076553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Participants will complete 12 sessions of CBT
Study NCT04076553 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CBT
Description: Participants will complete 12 sessions of CBT
Study NCT04076553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICT
Description: Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12
Study NCT03630601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo PAI
Study NCT04373733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Anti-viral
Study NCT04373733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care management
Description: Standard of care management for COVID-19
Study NCT04373733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care management
Description: Standard of care management for COVID-19
Study NCT03033628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection using DentalVibe comfort system
Description: giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
Study NCT00520130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Chemotherapy
Description: Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3
Study NCT03033628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional dental injection
Description: giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
Study NCT01044199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCEC rabies vaccine given intradermally
Description: PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
Study NCT01044199 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCEC rabies vaccine administered intramuscularly
Description: PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
Study NCT01751685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kyphosis-specific spinal strengthening exercises
Description: Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
Study NCT01751685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: monthly educational lectures on various topics
Study NCT04625972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
Study NCT04625972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (× 2 IM injections) of saline placebo on Day 1.
Study NCT01859091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT02390388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pudendal nerve block
Description: nerve stimulator-guided Pudendal block
Study NCT02390388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block
Study NCT02069184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: 1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
Study NCT02069184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline as placebo
Description: 100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
Study NCT01463345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
Study NCT01463345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
Study NCT04864769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill protein hydrolysate
Description: Ingestion of 35 g Krill protein hydrolysate
Study NCT04864769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein isolate
Description: Ingestion of 35 g Soy protein isolate
Study NCT04864769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Ingestion of 35 g Whey protein isolate
Study NCT04704804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Synthetic CT Scan
Description: method of generating CT-synthetic image from MRI
Study NCT04864769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Ingestion of water (control)
Study NCT04267042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
Study NCT04267042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal Atomization Device
Description: MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
Study NCT04267042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation
Description: INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
Study NCT01107457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously
Study NCT01107457 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered subcutaneously
Study NCT01107457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT02850562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
Study NCT02850562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking + Exercise
Description: The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
Study NCT03319888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: continuous positive pressure in the airway
Study NCT03319888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: conservative treatment group with lifestyle modifications
Study NCT00520130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMS
Description: Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
Study NCT00520130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLAG
Description: Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
Study NCT00520130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-F
Description: Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
Study NCT00520130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
Study NCT04478435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose loaded clear fluid
Description: Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
Study NCT04478435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glucose loaded clear fluid
Description: Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
Study NCT01083784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of prophylactic anticonvulsants (valproate, clonazepam)
Description: start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
Study NCT01083784 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Control group
Description: Control group
Study NCT00007605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
Study NCT00007605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
Study NCT00960297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
Study NCT00960297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
Study NCT00960297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
Study NCT00833157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulphate
Description: Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.
Study NCT00833157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks
Study NCT00833157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
Study NCT03283410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol plasmatic concentration (Marsh)
Study NCT02210598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inpatient Foley balloon induction
Description: The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
Study NCT02210598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: outpatient Foley balloon induction
Description: The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
Study NCT02210598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement.
Study NCT02210598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement.
Study NCT00690261 — intervention group
Intervention type: OTHER
Description: No intervention in this study
Study NCT03960450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-475
Description: topical cream
Study NCT03960450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical cream
Study NCT05657522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid molar intruder
Description: The rapid molar intruder was applied.
Study NCT00864019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline HCl 100 mg tablets, single dose
Description: A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
Study NCT00864019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
Study NCT03400085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth application
Description: The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
Study NCT04319237 — intervention group
Intervention type: OTHER
Intervention: Handgrip strength test
Description: The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)
Description: The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales.
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)
Description: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Assessment - Color Trails
Description: The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Assessment -Stroop Color and Word Test
Description: The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire
Description: The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
Description: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
Study NCT00187720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given a single oral dose of 850 mg of metformin
Study NCT05093309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Webinar
Description: At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.
Study NCT05093309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources
Description: After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.
Study NCT05093309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
Study NCT02856347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 18F-DOPA
Description: Injection of 18F-DOPA and PET / CT-scan assessment